SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, ...
The Breakthrough Therapy designation, introduced by the NMPA, is a key initiative aimed at accelerating the development and approval of innovative medicines that offer significant clinical benefits.
A newer regimen was no more effective than an older regimen when both were compared for graft versus host disease (GVHD) prophylaxis in patients who underwent reduced-intensity conditioning followed ...
Cytokine release syndrome occurred in 33 and 24% of participants in the ATG 2.5- and 0.5mg/kg groups, respectively, and in no participants in the placebo group. HealthDay News — Antithymocyte globulin ...
ATG 2.5 and 0.5 mg/kg reduces loss of β-cell function in young people with recent-onset type 1 diabetes. (HealthDay News) — Antithymocyte globulin (ATG) 2.5 and 0.5 mg/kg reduces loss of β-cell ...
SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results